DE10019154A1 - Zellbindende Nukleinsäuremoleküle (Aptamere) - Google Patents
Zellbindende Nukleinsäuremoleküle (Aptamere)Info
- Publication number
- DE10019154A1 DE10019154A1 DE10019154A DE10019154A DE10019154A1 DE 10019154 A1 DE10019154 A1 DE 10019154A1 DE 10019154 A DE10019154 A DE 10019154A DE 10019154 A DE10019154 A DE 10019154A DE 10019154 A1 DE10019154 A1 DE 10019154A1
- Authority
- DE
- Germany
- Prior art keywords
- nucleic acid
- acid molecule
- acid molecules
- seq
- aptamers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 109
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 108
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 108
- 108091023037 Aptamer Proteins 0.000 title description 37
- 230000027455 binding Effects 0.000 title description 15
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000012620 biological material Substances 0.000 claims abstract description 13
- 210000002889 endothelial cell Anatomy 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 18
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000007781 signaling event Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- -1 against Theo phylin Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000009843 endothelial lesion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 229940011399 escin Drugs 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10019154A DE10019154A1 (de) | 2000-04-18 | 2000-04-18 | Zellbindende Nukleinsäuremoleküle (Aptamere) |
| EP01929568A EP1294938B1 (de) | 2000-04-18 | 2001-04-17 | Zellbindende nukleinsäuremoleküle (aptamere) |
| PCT/EP2001/004340 WO2001079538A2 (de) | 2000-04-18 | 2001-04-17 | Zellbindende nukleinsäuremoleküle (aptamere) |
| AT01929568T ATE382098T1 (de) | 2000-04-18 | 2001-04-17 | Zellbindende nukleinsäuremoleküle (aptamere) |
| JP2001577520A JP2004503214A (ja) | 2000-04-18 | 2001-04-17 | 細胞結合核酸分子（アプタマー） |
| DE50113417T DE50113417D1 (de) | 2000-04-18 | 2001-04-17 | Zellbindende nukleinsäuremoleküle (aptamere) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10019154A DE10019154A1 (de) | 2000-04-18 | 2000-04-18 | Zellbindende Nukleinsäuremoleküle (Aptamere) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10019154A1 true DE10019154A1 (de) | 2001-10-31 |
Family
ID=7639154
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10019154A Ceased DE10019154A1 (de) | 2000-04-18 | 2000-04-18 | Zellbindende Nukleinsäuremoleküle (Aptamere) |
| DE50113417T Expired - Fee Related DE50113417D1 (de) | 2000-04-18 | 2001-04-17 | Zellbindende nukleinsäuremoleküle (aptamere) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50113417T Expired - Fee Related DE50113417D1 (de) | 2000-04-18 | 2001-04-17 | Zellbindende nukleinsäuremoleküle (aptamere) |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1294938B1 (https=) |
| JP (1) | JP2004503214A (https=) |
| AT (1) | ATE382098T1 (https=) |
| DE (2) | DE10019154A1 (https=) |
| WO (1) | WO2001079538A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004055153A3 (de) * | 2002-12-17 | 2005-05-12 | Univ Eberhard Karls | Mit die adhäsion von biologischem material vermittelnden substanzen beschichtete vorrichtungen |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2924287T3 (es) * | 2009-04-08 | 2022-10-05 | Univ California | Conjugados de ADN-células |
| US8563711B2 (en) * | 2009-06-01 | 2013-10-22 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid aptamer capable of binding specifically to pancreatic cancer cells or tissues and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996034875A1 (en) * | 1995-05-03 | 1996-11-07 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| WO1999007724A1 (en) * | 1997-08-05 | 1999-02-18 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| WO1999027138A1 (en) * | 1997-11-21 | 1999-06-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
-
2000
- 2000-04-18 DE DE10019154A patent/DE10019154A1/de not_active Ceased
-
2001
- 2001-04-17 JP JP2001577520A patent/JP2004503214A/ja active Pending
- 2001-04-17 DE DE50113417T patent/DE50113417D1/de not_active Expired - Fee Related
- 2001-04-17 EP EP01929568A patent/EP1294938B1/de not_active Expired - Lifetime
- 2001-04-17 WO PCT/EP2001/004340 patent/WO2001079538A2/de not_active Ceased
- 2001-04-17 AT AT01929568T patent/ATE382098T1/de not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996034875A1 (en) * | 1995-05-03 | 1996-11-07 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US6013443A (en) * | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
| WO1999007724A1 (en) * | 1997-08-05 | 1999-02-18 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| WO1999027138A1 (en) * | 1997-11-21 | 1999-06-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
Non-Patent Citations (2)
| Title |
|---|
| Biochemistry 33 (1994) 10450-10456 * |
| Biochemistry 37 (1998) 6857-6863 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004055153A3 (de) * | 2002-12-17 | 2005-05-12 | Univ Eberhard Karls | Mit die adhäsion von biologischem material vermittelnden substanzen beschichtete vorrichtungen |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001079538A3 (de) | 2003-01-16 |
| ATE382098T1 (de) | 2008-01-15 |
| DE50113417D1 (de) | 2008-02-07 |
| EP1294938B1 (de) | 2007-12-26 |
| EP1294938A2 (de) | 2003-03-26 |
| WO2001079538A2 (de) | 2001-10-25 |
| JP2004503214A (ja) | 2004-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0517024B1 (de) | Tetravalente bispezifische Rezeptoren, ihre Herstellung und Verwendung | |
| Borrell et al. | Reelin regulates the development and synaptogenesis of the layer-specific entorhino-hippocampal connections | |
| DE69431285T2 (de) | Herstellungsmethode von markierten genen; transcripten und proteinen | |
| DE69432315T2 (de) | ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT | |
| DE3855064T2 (de) | Selektive Amplifikation von Oligonukleotiden-Zielsequenzen | |
| DE68923704T2 (de) | Technikken zur vermehrung und subtraktion von dns. | |
| DE69433816T2 (de) | Die bestimmung von nukleinsäuremutationen durch analyse des sputum | |
| DE69534802T2 (de) | Verfahren von in Neuriten lokalisierten mRNAs zur medizinischen Diagnose und Therapie | |
| DE69034197T2 (de) | Genomische Klonierung und Kartographie | |
| DE69838544T2 (de) | Isolierung von gewebespezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane | |
| EP0655926B1 (de) | Neue sonde zur tumordiagnostik oder tumortherapie | |
| DE19625191A1 (de) | Nierenkarzinom-spezifische T-Zellen | |
| DE10019154A1 (de) | Zellbindende Nukleinsäuremoleküle (Aptamere) | |
| DE4428651C1 (de) | Verfahren zur Herstellung und Amplifikation von Nukleinsäuren | |
| DE69432120T2 (de) | Mit chemotherapeutische zusammensetzungenassoziierten genetischen suppressor-elementen | |
| EP2373813B1 (de) | Verfahren zum nachweis methicillin-resistenter staphylococcus aureus (mrsa)-stämme | |
| JP2003527398A (ja) | 内皮特異性ターゲティング | |
| EP1162276A2 (de) | mRNA Moleküle zur Verwendung als Indikatoren für den Aktivierungs- und Funktionszustand von T-Lymphozyten | |
| DE102006026191A1 (de) | Vorrichtung und Substanz zur Isolierung von mesenchymalen Stammzellen (MSC) | |
| US20140369934A1 (en) | dsRNA/DNA Hybrid Genome Replication Intermediate Of Metakaryotic Stem Cells | |
| EP1831246B1 (de) | Sonde zum nachweis von nukleinsäuren | |
| DE69112309T2 (de) | Verfahren zum Nukleinsäurenachweis. | |
| DE112004002408B4 (de) | Verfahren zur Gewinnung einer angereicherten Population von siRNA-exprimierenden Zellen | |
| DE102016216657B4 (de) | Eukaryotische adulte Zellen umfassend ein Transfektionssystem und deren Herstellung und Verwendung | |
| RU2530170C1 (ru) | Способ детекции стволовых раковых клеток |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |